5-(2-Fluorophenyl)-1-Pyridin-3-Ylsulfonylpyrrole-3-Carbaldehyde

5-(2-Fluorophenyl)-1-Pyridin-3-Ylsulfonylpyrrole-3-Carbaldehyde (CAS 881678-39-9) is supplied as a pale-yellow crystalline solid with a nominal purity ≥ 98.0% (HPLC, area % at 254 nm). Trace moisture specification is held at ≤ 0.3% w/w (Karl Fischer titration, USP 〈921〉 Method Ic) to suppress aldehyde hydrate formation during ambient storage. The compound is routinely handled under dry nitrogen blanket and shipped in amber glass containers pre-purged to ≤50 ppm O₂. The following application modules describe validated downstream process routes, each identifying the relevant regulatory framework, stoichiometric usage window, unit-operation sequence, and final article type.

When Aldehyde Reactivity Drives Covalent Target Engagement

Targeted covalent inhibitors (TCIs) that exploit a reversible aldehyde warhead depend on precise control of water activity throughout the reaction cascade. In the construction of a pyridine-3-sulfonylpyrrole-based inhibitor directed at a non-catalytic cysteine in an oncogenic kinase, the carbaldehyde is coupled with an amine-containing hinge-binder fragment under strictly anhydrous conditions. The aldehyde is pre-dried by azeotropic distillation with anhydrous toluene (50–55 °C, 80 mbar) until KF analysis returns ≤15 ppm H₂O, then dissolved in anhydrous N,N-dimethylacetamide (DMAc, moisture spec. ≤30 ppm) containing molecular sieves 3 Å. A stoichiometric range of 1.05–1.15 molar equivalents of the aldehyde relative to the primary amine partner is employed; excursions above 1.20 equivalents provoke measurable oxime formation via trace nitrosating species, while ratios below 1.02 equivalents leave unreacted amine that interferes with the subsequent Pd-catalyzed Suzuki coupling on the pyrrole C-4 position. The condensation is performed in a jacketed Hastelloy C22 reactor equipped with a retreat-blade impeller, maintaining an internal temperature of 20–22 °C for 18–22 h. Reaction progress is monitored by in situ ReactIR (Mettler Toledo) tracking the aldehyde C=O stretch at 1695–1705 cm⁻¹; endpoint is defined as a signal loss of ≥97% peak area. Upon completion, the mixture is quenched with 0.5 M phosphate buffer (pH 6.8) and the crude imine intermediate is extracted into 2-methyltetrahydrofuran and concentrated on a wiped-film evaporator (Pope, 80 °C jacket, 0.5 mbar). Compliance framework: ICH M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities, with the free aldehyde classed as a Class 3 structural alert requiring confirmatory Ames testing (OECD 471). The isolated imine is carried forward without purification to a Pd(PPh₃)₄-mediated coupling step, ultimately delivering a reversible covalent kinase inhibitor formulated as an amorphous solid dispersion (HPMCAS-MF, spray-dried) for Phase I oncology trials. Process critical quality attributes include residual DMAc ≤ 410 ppm (ICH Q3C Option 2) and Pd ≤ 5 ppm (USP 〈232〉/〈233〉). The operational boundary of 20–22 °C for the imine formation is non-negotiable: at 25 °C, side-product drift reaches 1.2% per hour, consuming the electrophile in an irreversible hydrate pathway.

In the manufacture of pyrrole-containing insecticidal nitriles derived from chlorfenapyr-class pharmacophores, the 3-formyl group serves as a latent nitrile precursor. The aldehyde is first converted to its oxime using hydroxylamine hydrochloride (1.08 mol equiv) in a 3:1 (v/v) ethanol/pyridine medium at 60–65 °C for 3 h. The resulting oxime is isolated by drowning in ice-water (0–5 °C), filtered through a Nutsche filter, and dehydrated to the nitrile with Vilsmeier reagent (POCl₃/DMF, 0–5 °C to 25 °C over 4 h) in 1,2-dichloroethane. The downstream process yields a 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)pyrrole-3-carbonitrile intermediate that is incorporated into emulsifiable concentrate (EC) formulations at a loading of 10% w/v. Compliance is verified against FAO Specification 267/EC (2019) for EC insecticides, with CIPAC MT 36.3 used for emulsion stability and re-emulsification testing. The formyl-to-nitrile sequence typically consumes 1.10–1.15 molar equivalents of the aldehyde relative to the desired nitrile final intermediate. This unlabeled block terminates with the registration of a crop protection product falling under US EPA 40 CFR Part 158 product chemistry data requirements.

A Pyridine-Sulfonamide Moiety in Type II Kinase Inhibitor Scaffolds

The sulfonylpyridine appendage on this building block pre-organizes a key hydrogen-bonding network with the DFG-out conformation of a range of receptor tyrosine kinases. In a convergent synthetic route validated at pilot scale, the aldehyde is employed as the electrophilic anchor for a 2-aminopyrimidine fragment, forming a Schiff base that is subsequently reduced in situ with sodium triacetoxyborohydride (STAB, 1.5–1.8 mol equiv) in 1,2-dimethoxyethane at 0–10 °C. Addition ratio is tightly controlled at 0.95–1.00 molar equivalents of the aldehyde per mole of amine to compensate for the aldehyde's propensity to form a bis-adduct; an excess of amine above 1.02 equivalents leads to premature N-alkylation of the pyrrole nitrogen, a side reaction verified by LC-HRMS (Q-TOF, Agilent 6545) that depletes the desired mono-amine intermediate by 8–12% relative area. The reduction is carried out in a 1000 L glass-lined reactor with a pitched-blade turbine, pH monitored continuously by an in-line Knick probe (target apparent pH 4.5–5.0). Upon completion, the organic phase is washed with 10% w/v aqueous potassium sodium tartrate, dried over MgSO₄, and concentrated on a 22-inch rotavap at 35 °C bath. The crude secondary amine is then engaged in a Buchwald-Hartwig amination with a halogenated quinazoline, ultimately affording a Type II VEGFR2/PDGFRβ dual inhibitor formulated as a hydrochloride salt for oral administration. All steps are executed under ICH Q7 GMP for active pharmaceutical ingredients, with the starting material aldehyde justified per ICH Q11 Section 3.2 and an impurity fate map documented for related substances at ≥0.10% reporting threshold (ICH Q3A(R2)). Residual boron (from STAB) is monitored by ICP-OES and must remain below 5 μg/g (USP 〈232〉).

Conjugation to Fluorescent Probes Through an Aldehyde Handle

When amino-functionalized cyanine or Alexa Fluor dyes are decorated with this pyrrole carbaldehyde, the resultant Schiff base conjugate serves as a targeted bioimaging agent with a built-in polarity-sensitive fluorophore environment. The aldehyde (1.2–1.5 molar equivalents vs. amino-dye) is dissolved in anhydrous DMSO (10 mg/mL) and added dropwise to a solution of the dye-amine in 0.1 M bicarbonate buffer (pH 8.3–8.5) containing 5% v/v DMF. The mixture is stirred at 25 ± 1 °C in the dark; imine formation reaches > 95% conversion within 45–60 min as monitored by absorbance shift from 650 nm to 678 nm (Cyanine5). The crude conjugate is purified by size-exclusion chromatography (Sephadex G-25, PD-10 column) with PBS eluent, and the product fraction is lyophilized (VirTis Genesis, shelf temperature -40 °C, 50 mTorr) to obtain a deep-blue lyophilate. The conjugate is intended for confocal microscopy studies of kinase translocation; photostability is benchmarked against a non-reactive analogue. Quality requirements follow ISO 13485:2016 for research-use-only fluorescent probes, with endotoxin testing per USP 〈85〉 applied when the probe is used in live-cell imaging. The major process failure mode is hydrolysis of the imine during silica gel chromatography — hence the switch to a purely aqueous SEC protocol.

How Does the 2-Fluorophenyl Substituent Influence Metabolic Stability?

Early-stage antifungal lead optimization programs exploit the 2-fluorophenyl motif of this intermediate to attenuate oxidative metabolism at the para position of the pyrrole core. In the synthesis of hybrid pyrrole-triazole antifungal agents, the aldehyde is reacted with propargylamine (1.0 mol equiv) in refluxing ethanol to furnish the corresponding propargyl imine, which is then subjected to Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) with an azidomethyl-substituted fluconazole analogue. Catalyst system: CuSO₄·5H₂O (0.05 equiv)/sodium ascorbate (0.15 equiv) in 1:1 t-BuOH/H₂O at 25–30 °C. The addition ratio of the aldehyde-based alkyne component to azide is fixed at 1.05:1.00 to drive triazole formation to completion; residual alkyne is scavenged by a polystyrene-bound azide resin (loading capacity 1.0 mmol/g, 2.0 equiv) for 2 h at 25 °C. The resulting triazole hybrid, after filtration and flash chromatography (Biotage Isolera, SNAP Ultra cartridge, gradient EtOAc in heptane 0–80%), exhibits a log D₇.₄ shift of −0.3 units relative to the des-fluoro analogue, consistent with attenuated CYP51 binding clearance in human liver microsomes. The complete sequence is scaled in a 20 L jacketed glass reactor and falls under the chemical development GMP framework of ICH Q7 if the triazole is progressed as a clinical candidate. Terminal dosage form is an intravenous solution requiring the active compound to meet USP 〈788〉 particulate matter limits (≥10 μm: ≤ 6000 per container). Precaution: the free aldehyde is incompatible with nucleophilic solvents such as dimethyl sulfoxide on prolonged heating; storage at -20 °C under argon is mandated when not in use beyond 12 h.

For the chelation-assisted synthesis of ^99mTc radiopharmaceuticals, the aldehyde is converted to a thiosemicarbazone which coordinates the oxotechnetium core. Formulation begins with condensation of the aldehyde (1.0 mmol) and N-methyl thiosemicarbazide (1.03 mmol) in absolute ethanol with a catalytic amount of acetic acid (10 µL). The mixture is heated under reflux (78°C) for 3.5 h. Solvent is removed on a rotary evaporator at 40°C, and the residue is triturated with cold diethyl ether to yield the thiosemicarbazone ligand as a pale-yellow powder. The ligand is then lyophilized in kit vials containing stannous chloride (75 µg) and sodium tartrate (10 mg), which upon addition of generator-eluted ^99mTcO₄⁻ (1.0–3.0 GBq) and heating at 100°C for 15 min produces the neutral lipophilic complex with radiochemical purity > 95% by ITLC-SG. The finished product is a sterile injection governed by European Pharmacopoeia monograph 1186 (Radiopharmaceutical Preparations) and USP 〈823〉. The terminal sterile filtration uses a 0.22 μm PVDF membrane, and the product must be used within 6 h post-reconstitution.